Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
Provided By GlobeNewswire
Last update: Oct 16, 2024
SAN MATEO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Phase 2b data demonstrating the anti-fibrotic activity of its fatty acid synthase (FASN) inhibitor, denifanstat, and preclinical data demonstrating atherosclerosis improvement with FASN inhibitor treatment, will be highlighted in three presentations at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2024, taking place November 15-19, 2024 in San Diego, California.
7.4
-0.87 (-10.52%)
Find more stocks in the Stock Screener
SGMT Latest News and Analysis
5 days ago - ChartmillHere are the top movers in Thursday's session.Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.
13 days ago - ChartmillThese stocks are moving in today's pre-market sessionAs we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
